Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,128 public trials 2,031 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Active, not recruiting

A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

NCT06622226

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • Nagoya City University Hospital Nagoya, Aichi-ken, Japan
  • National Hospital Organization Shibukawa Medical Center Shibukawa-shi, Gunma, Japan
  • Hiroshima Red Cross Hospital Atomic-bomb Survivors Hospital Hiroshima, Japan
  • National Hospital Organization Sendai Medical Center Sendai, Miyagi, Japan
View Trial Details
Active, not recruiting

Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

NCT06093841

Conditions
Follicular Lymphoma Grade 3B, Hemic and Lymphatic Diseases, High-grade B-cell Lymphoma, +11 more
Locations
  • Sun Yat-sen University Cancer Hospital Guangzhou, Guangdong, China
  • Henan Cancer Hospital Zhengzhou, Henan, China
  • The First Affiliated Hospital of Zhengzhou University Zhengzhou, Henan, China
  • Hunan Cancer Hospital Changsha, Hunan, China
View all 13 locations
View Trial Details
Active, not recruiting

BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma

NCT03264131

Conditions
Adult T-Cell Leukemia/Lymphoma, Hematologic Diseases, Hemic and Lymphatic Diseases, +11 more
Locations
  • South Broward/Memorial Healthcare System Hollywood, Florida, United States
  • Boston Medical Center Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center (BIDMC) Boston, Massachusetts, United States
  • Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill Chapel Hill, North Carolina, United States
View Trial Details
Active, not recruiting

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

NCT03212404

Conditions
Adenocarcinoma, Adenoma, Bronchial Neoplasms, +67 more
Locations
  • Research Site Wollongong, New South Wales, Australia
  • Research Site Benowa, Queensland, Australia
  • Research Site Buderim, Queensland, Australia
  • Research Site Greenslopes, Queensland, Australia
View all 48 locations
View Trial Details
Active, not recruiting

Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL

NCT04722848

Conditions
ALL, Adult, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Hematologic Diseases, +11 more
Locations
  • Area Vasta N. 5 Ascoli Piceno - S. Benedetto Del Tronto, Presidio Ospedaliero Av5 Osp. Gen. Prov.Le "C.G.Mazzoni" - Uoc Ematologia Ascoli Piceno, Italy
  • Irccs Oncologico Istituto Tumori Giovanni Paolo Ii - Bari - Uo Ematologia Bari, Italy
  • Asst Papa Giovanni Xxiii - Ospedale Di Bergamo - Sc Ematologia Bergamo, Italy
  • As Dell'Alto Adige, Ospedale Centrale Di Bolzano - Ematologia E Centro Trapianto Midollo Osseo Bolzano, Italy
View all 15 locations
View Trial Details
Active, not recruiting

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

NCT04782687

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +18 more
Locations
  • Arizona Oncology Associates, PC - HOPE Tucson, Arizona, United States
  • Rocky Mountain Cancer Centers Denver, Colorado, United States
  • Maryland Oncology Hematology, P.A. Columbia, Maryland, United States
  • New York Oncology Hematology, P.C. Albany, New York, United States
View Trial Details

Related conditions